Trial Profile
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Ipilimumab; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms EMPOWER-lung 3
- Sponsors Regeneron Pharmaceuticals
- 04 Feb 2024 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 07 Dec 2023 According to Regeneron Pharmaceutical media release, data from this study presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO)
- 07 Dec 2023 Results published in the Regeneron Pharmaceutical Media Release